Published in Clin Cancer Res on September 15, 2004
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLoS One (2013) 1.14
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J (2015) 1.03
Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis (2011) 0.99
Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther (2012) 0.98
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res (2015) 0.92
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer (2006) 0.91
Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol (2010) 0.87
Metastatic bone tumors: Analysis of factors affecting prognosis and efficacy of CT and (18)F-FDG PET-CT in identifying primary lesions. Mol Clin Oncol (2014) 0.84
Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. BMC Med Res Methodol (2015) 0.81
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. Can Urol Assoc J (2013) 0.79
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep (2015) 0.79
Hand metastasis: an unusual presentation of renal cell carcinoma. Hand (N Y) (2012) 0.77
Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis (2014) 0.76
Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma. Oncotarget (2017) 0.75
Transient ischaemic attack secondary to paraneoplastic erythrocytosis. BMJ Case Rep (2014) 0.75
Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials. J Bone Oncol (2012) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
A high-resolution map of active promoters in the human genome. Nature (2005) 24.35
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Superoxide flashes in single mitochondria. Cell (2008) 4.08
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
DNA sequence motifs for structure-specific recognition and separation of carbon nanotubes. Nature (2009) 3.23
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25
Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med (2012) 2.25
An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest (2008) 2.19
miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest (2013) 2.11
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer (2003) 2.04
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Prominent roles of the NorR and Fur regulators in the Escherichia coli transcriptional response to reactive nitrogen species. Proc Natl Acad Sci U S A (2004) 1.81
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res (2010) 1.74
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol (2003) 1.70
Discovery of Fur binding site clusters in Escherichia coli by information theory models. Nucleic Acids Res (2007) 1.67
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
Subtype-specific alpha1- and beta-adrenoceptor signaling in the heart. Trends Pharmacol Sci (2006) 1.65
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer (2006) 1.51
Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis. J Biol Chem (2007) 1.50
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res (2003) 1.48
Therapy and outcome of small cell carcinoma of the kidney: report of two cases and a systematic review of the literature. Cancer (2003) 1.42
Exercise heart rate monitors for anxiety treatment in a rural primary care setting: a pilot study. Fam Med (2013) 1.40
Sunitinib in advanced renal cell carcinoma: new treatment option? Curr Oncol Rep (2007) 1.39
Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci (2004) 1.38
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer (2012) 1.36
p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res (2002) 1.34
Imaging superoxide flash and metabolism-coupled mitochondrial permeability transition in living animals. Cell Res (2011) 1.32
The role of interleukin-1 in wound biology. Part II: In vivo and human translational studies. Anesth Analg (2010) 1.32
Superoxide flashes: early mitochondrial signals for oxidative stress-induced apoptosis. J Biol Chem (2011) 1.31
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer (2009) 1.30
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res (2005) 1.30
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys (2004) 1.25
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer (2010) 1.22
Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol (2010) 1.22
H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. MBio (2011) 1.22
Calcium gradients underlying cell migration. Curr Opin Cell Biol (2011) 1.19
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer (2007) 1.19
Cardioprotection by CaMKII-deltaB is mediated by phosphorylation of heat shock factor 1 and subsequent expression of inducible heat shock protein 70. Circ Res (2009) 1.18
Kissing and nanotunneling mediate intermitochondrial communication in the heart. Proc Natl Acad Sci U S A (2013) 1.18
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res (2009) 1.18
The role of interleukin-1 in wound biology. Part I: Murine in silico and in vitro experimental analysis. Anesth Analg (2010) 1.16
The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res (2005) 1.15
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest (2002) 1.13
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther (2012) 1.11
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer (2004) 1.11
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
Central role of mitofusin 2 in autophagosome-lysosome fusion in cardiomyocytes. J Biol Chem (2012) 1.10
Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep (2009) 1.09
Response to "A critical evaluation of cpYFP as a probe for superoxide". Free Radic Biol Med (2011) 1.09
High-resolution length sorting and purification of DNA-wrapped carbon nanotubes by size-exclusion chromatography. Anal Chem (2005) 1.08
Synergistic triggering of superoxide flashes by mitochondrial Ca2+ uniport and basal reactive oxygen species elevation. J Biol Chem (2013) 1.08
Fluorescence efficiency of individual carbon nanotubes. Nano Lett (2007) 1.07
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol (2006) 1.05
Superoxide flashes: elemental events of mitochondrial ROS signaling in the heart. J Mol Cell Cardiol (2012) 1.04
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer (2009) 1.04
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer (2009) 1.04
Pazopanib. Nat Rev Drug Discov (2010) 1.02
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets (2008) 1.02
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer (2010) 1.02
Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol (2010) 1.02
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer (2006) 1.02
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
Theory of structure-based carbon nanotube separations by ion-exchange chromatography of DNA/CNT hybrids. J Phys Chem B (2005) 1.01
Spontaneous partition of carbon nanotubes in polymer-modified aqueous phases. J Am Chem Soc (2013) 0.99
Superoxide flashes reveal novel properties of mitochondrial reactive oxygen species excitability in cardiomyocytes. Biophys J (2012) 0.99
Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. Bioorg Med Chem Lett (2007) 0.99
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep (2005) 0.98
An integrative genomic analysis identifies Bhmt2 as a diet-dependent genetic factor protecting against acetaminophen-induced liver toxicity. Genome Res (2009) 0.98